Novavax COVID-19 vaccine, flu shot coadministration likely ‘viable strategy,’ company says
Fox News
Maryland-based biotech company Novavax on Monday announced its experimental COVID-19 vaccine remained effective when coadministered with an approved flu shot.
Preliminary findings from a Phase 3 clinical trial, posted ahead of peer review, involved 431 volunteers in the U.K. enrolled in a coadministration sub-study, in which all participants received an approved flu shot. About half also received the company’s investigational COVID-19 vaccine while the rest were given placebo.More Related News